Loading
Life sciences · Journal article
Nutrition & Food Science · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Purpose This study aims to investigate the protective effects and underlying mechanisms of astaxanthin (AST), a potent natural carotenoid, against high-fat diet (HFD)-induced steatohepatitis, a key stage in nonalcoholic fatty liver disease (NAFLD). Design/methodology/approach Male C57BL/6 mice were fed a normal diet (ND) or a 60% HFD for 6 weeks. HFD-fed mice were further divided into groups receiving either a vehicle or AST supplementation at 50 or 150 mg/kg/day via oral gavage. Systemic metabolic parameters (body composition, insulin resistance, lipid profiles, adipokines), hepatic steatosis (histology, lipid content), oxidative stress markers including reactive oxygen species (ROS), malondialdehyde (MDA), glutathione (GSH), total antioxidant capacity (T-AOC), inflammation including tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6), phosphorylated nuclear factor-kappa B p65 (p-NF-κB p65) and the expression of key lipogenic genes (Srebp1c, Fasn, Acaca, Scd1, Hmgcr) were analyzed. Findings AST supplementation dose-dependently attenuated HFD-induced systemic metabolic disturbances, including obesity, adipokine imbalance (normalized leptin/adiponectin ratio), insulin resistance (reduced HOMA-IR) and dyslipidemia. In the liver, AST markedly alleviated steatosis, oxidative stress and pro-inflammatory cytokine production. Mechanistically, these benefits were associated with the downregulation of the master lipogenic transcription factor sterol regulatory element-binding protein 1c (SREBP1c) and its downstream target genes (Fasn, Acaca, Scd1), thereby suppressing de novo lipogenesis. Originality/value This study provides the evidence that AST protects against HFD-induced early steatohepatitis through a coordinated mechanism involving the transcriptional repression of SREBP1c to concurrently inhibit hepatic lipogenesis and mitigate oxidative stress. This dual-pathway intervention highlights the value of AST as a multi-targeting modulator for managing diet-induced NAFLD.